Dear Editor, The current evidence base for surgical treatment of chronic low back pain (CLBP) was on the agenda during two crowded workshop sessions in SPINEWEEK in Porto, Portugal last June, one under the guidance of the SEE and one under the guidance of the ISSLS. Among other issues, the necessity of conducting scientific studies in order to widen our knowledge about the causes and treatment strategies-including patient selectionwas discussed. There was quite an agreement on the difficulties in conducting randomized, controlled, trials (RCTs) in our field, but strangely enough, this insight seemed to lead to the feeling that the results already available from such studies should not be reliable as evidence today. This was illustrated by the response from the audience on the following question (sic) put forward by John O'Dowd, who was moderating the ISSLS session: ''Do you think that there are any real scientific evidence supporting our way of treating our spine patients today?'' Almost no spine surgeons raised their hands.It should be important to consider that we do have evidence-based facts, obtained through several well-conducted, large, RCTs. For example, if one uses the treatment strategies in the studies referred to, the following evidence applies to lumbar fusion in selected patients with CLBP: patients with CLBP can be treated with lumbar fusion [6, 13] . Generally, instrumentation does not improve clinical results [1, 7, 12, 16] . Generally, inter-body fusion does not seem to improve clinical results compared with posterolateral fusion [7] , although this is a matter of debate [2a] . Complications increase with increasing procedure technicality [5] . Clinical results obtained from fusion or rehabilitation converge with time [3, 9] . Disc narrowing of >50% predicts better outcome after lumbar fusion [11] . There are indications on the following: bio-psycho-social rehabilitation clinically equals lumbar fusion after 2 years [2, 4] . Surgery is more costly than non-specific rehabilitation after 2 years [8] . As for costs and treatment effects, it is important to consider that cost-effectiveness is dependent on what the fund holders wants to pay for extra treatment effects achieved by the use of one treatment instead of another [10] .
Consequently, the scientific frontier today regarding surgical treatment for CLBP is no longer: ''is it consistent with evidence-based medicine (EBM) to fuse painful lumbar segments?'' That question has already been answered with: ''yes, in selected patients '' [15] . The frontier is instead: ''when and how should we use lumbar fusion procedures'', and ''when and how should we use rehabilitation''? In other words: patient selection and procedure selection.
The conclusions made, and the advice given by the Cochrane collaboration group, is obviously extremely important, but, in a fast changing reality with market-launched solutions with a survival time of maybe not more than a couple of years, this group, heavily depending on RCTs for its evidence-based conclusions, cannot always give relevant answers to current questions. The choice between a strict conservative approach, where no procedures are used before being tested in randomized, controlled, trials, and a perhaps more pragmatic approach, where new techniques are tested because the concept fits ''personal and professional experience'', is sometimes not easy to make.
The RCT is the gold standard, where, ideally, two treatment concepts can be compared in a homogenous patient population. However, these studies are time consuming and costly and depend on dedicated co-workers, often over a period of many years. Apart from this, the external validity may be low, i.e. the results may not be generally applicable. It has, therefore, become clear to many spine surgeons and scientists that answers have also to be looked for through other less sophisticated but correctly conducted and repeated, comparably reliable studies, such as case-control studies and case series. It is important that we strive to include our patients in these types of studies, should the RCT be considered too demanding, or maybe not even feasible. Health economic assessments should, preferably, be integrated in all studies.
However, all treated CLBP patients should be included in national or international registries to secure quality control and give the possibility of producing scientific reports. In a time when ''the market'' advocates surgical and increasingly technical solutions, which are often not adequately tested before they are launched on a large scale, this is an important mission. 
